Virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based treatment in clinical practice

被引：0
|
作者：
Armenia, D. [1 ]
Forbici, F. [2 ]
Bertoli, A. [3 ]
Berno, G. [2 ]
Malagnino, V. [4 ]
Gagliardini, R. [2 ]
Borghi, V. [5 ]
Gennari, W. [5 ]
Cicalini, S. [2 ]
Buonomini, A. [6 ]
Teti, E. [4 ]
Latini, A. [6 ]
Sarmati, L. [4 ]
Mussini, C. [5 ]
Andreoni, M. [4 ]
Antinori, A. [2 ]
Perno, C. F. [7 ]
Ceccherini-Silberstein, F. [3 ]
Santoro, M. M. [3 ]
机构：
[1] St Camillus Int Univ Hlth Sci, Rome, Italy
[2] IRCCS, Natl Inst Infect Dis L Spallanzani, Rome, Italy
[3] Univ Roma Tor Vergata, Rome, Italy
[4] Polyclin Rome Tor Vergata, Rome, Italy
[5] Polyclin Modena, Modena, Italy
[6] IRCCS, San Gallicano Dermatol Inst, Rome, Italy
[7] Bambino Gesu Pediat Hosp, Rome, Italy
来源：
HIV MEDICINE | 2021年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
BPD1/2
引用
收藏
页码：26 / 28
页数：3
相关论文
共 50 条
  • [1] Factors associated with virological response and resistance profile in virologically suppressed HIV-1 infected patients switching to a dual therapy containing integrase inhibitors in clinical practice
    Armenia, D.
    Gori, C.
    Forbici, F.
    Borghi, V.
    Gennari, W.
    Bertoli, A.
    Giannetti, A.
    Cicalini, S.
    Mondi, A.
    Colafigli, M.
    Lichtner, M.
    Andreoni, M.
    Mussini, C.
    Antinori, A.
    Silberstein, F. Ceccherini
    Perno, C.
    Santoro, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [2] Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment
    Armenia, Daniele
    Zaccarelli, Mauro
    Borghi, Vanni
    Gennari, William
    Di Carlo, Domenico
    Giannetti, Alberto
    Forbici, Federica
    Bertoli, Ada
    Gori, Caterina
    Fabeni, Lavinia
    Pinnetti, Carmela
    Marocco, Raffaella
    Latini, Alessandra
    Ceccherini-Silberstein, Francesca
    Mastroianni, Claudio Maria
    Mussini, Cristina
    Antinori, Andrea
    Perno, Carlo Federico
    Santoro, Maria Mercedes
    JOURNAL OF CLINICAL VIROLOGY, 2018, 104 : 61 - 64
  • [3] Virological response and resistance profile in highly treatment-experienced HIV-1-infected patients switching to dolutegravir plus boosted darunavir in clinical practice
    Armenia, Daniele
    Bouba, Yagai
    Gagliardini, Roberta
    Fabeni, Lavinia
    Borghi, Vanni
    Berno, Giulia
    Vergori, Alessandra
    Cicalini, Stefania
    Mussini, Cristina
    Antinori, Andrea
    Ceccherini-Silberstein, Francesca
    Perno, Carlo Federico
    Santoro, Maria Mercedes
    HIV MEDICINE, 2021, 22 (06) : 519 - 525
  • [4] Virological response of HIV-infected patients virologically suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score
    Charpentier, Charlotte
    Peytavin, Gilles
    Joly, Veronique
    Cabras, Ornella
    Perrier, Marine
    Minh Le
    Phung, Bao
    Yazdanpanah, Yazdan
    Descamps, Diane
    Landman, Roland
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [5] Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV with historical drug resistance mutations
    Chang, Ziwei
    Zhu, Hongyan
    Zhang, Yiting
    Chen, Yaling
    Li, Jiahui
    Qin, Jiamin
    Zhu, Yueping
    Wei, Hongxia
    Yang, Yongfeng
    Zou, Meiyin
    Qian, Feng
    Hu, Zhiliang
    CHINESE MEDICAL JOURNAL, 2024, 137 (22) : 2758 - 2760
  • [6] Effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV with historical drug resistance mutations
    Chang Ziwei
    Zhu Hongyan
    Zhang Yiting
    Chen Yaling
    Li Jiahui
    Qin Jiamin
    Zhu Yueping
    Wei Hongxia
    Yang Yongfeng
    Zou Meiyin
    Qian Feng
    Hu Zhiliang
    中华医学杂志英文版, 2024, 137 (22)
  • [7] Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals
    Armenia, D.
    Gagliardini, R.
    Alteri, C.
    Svicher, V.
    Cento, V.
    Borghi, V.
    Vergori, A.
    Cicalini, S.
    Forbici, F.
    Fabeni, L.
    Bertoli, A.
    Brugneti, M.
    Gennari, W.
    Malagnino, V.
    Andreoni, M.
    Mussini, C.
    Antinori, A.
    Perno, C. F.
    Santoro, M. M.
    Ceccherini-Silberstein, F.
    JOURNAL OF CLINICAL VIROLOGY, 2023, 168
  • [8] Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting
    Casado, Jose L.
    Monsalvo, Marta
    Fontecha, Maria
    Vizcarra, Pilar
    Rodriguez, Miguel A.
    Vivancos, Maria Jesus
    Moreno, Santiago
    HIV RESEARCH & CLINICAL PRACTICE, 2019, 20 (02) : 64 - 72
  • [9] Dolutegravir and rilpivirine for the maintenance treatment of virologically suppressed HIV-1 infection
    Casado, Jose L.
    Monsalvo, Marta
    Rojo, Aurora M.
    Fontecha, Maria
    Rodriguez-Sagrado, Miguel A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (06) : 561 - 570
  • [10] Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy
    Borghetti, A.
    Baldin, G.
    Ciccullo, A.
    Gagliardini, R.
    D'Avino, A.
    Mondi, A.
    Ciccarelli, N.
    Lamonica, S.
    Fanti, I.
    Trecarichi, E.
    Fabbiani, M.
    Cauda, R.
    De Luca, A.
    Di Giambenedetto, S.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (08) : 2359 - 2361
12345